![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
01 MEIJI SEIKA PHARMA CO., LTD. Tokyo JP (1)
01 Sodium hyaluronate, Intrinsic viscosity: 1.5 - 1.9 m3/kg; by fermentation; for parenteral administration, including intra-ocular and intra-articular administration (1)
01 Japan (1)
01 Valid (1)
20
Meiji Seika Pharma Co., Ltd. Tokyo Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Sodium hyaluronate, Intrinsic viscosity: 1.5 - 1.9 m3/kg; by fermentation; for parenteral administration, including intra-ocular and intra-articular administration, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2005-112 - Rev 00
This Chemical Type CEP, issued on July 10, 2012, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1472 associated with this CEP further emphasizes